gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BBOTHealthcarePharmaceuticals

BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)

$2.30−0.86%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$2.32▼ 81.12% in range
Nov 3, 2025Low $2.31 · High $13.73Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

BridgeBio Oncology Therapeutics closed at $2.30 on Nov 4, down 0.86%, within 0.0% of its 52-week closing low. Volume of 451.5K shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: -34.3% over one month, -72.4% over six months, -81.3% over one year.

Short interest was 3.8M shares at the Oct 15 settlement, up 14.0% from the prior report (13.9% of float, 7.1 days to cover).

Market cap$184.4M80.2M shares
Revenue · quarter$0.00—
Diluted EPS$-705.20—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range2.30 – 13.73−83.2% from high
Volume451.5K0.77× 20-day avg
Volatility · 60d87.9%Annualised
Short % of float13.9%7.1 days to cover
Net cash$225.7MCash $225.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −17.9%1M −34.3%3M −73.8%6M −72.4%YTD −81.6%1Y −81.3%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum11
Revenue growth—
Net margin—
Value (low P/E)—
Size47

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.8M+14.0% vs prior
Days to cover7.1Settled Oct 15
% of float13.9%
Short vol. 10d37.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BBOTBridgeBio Oncology Therapeutics$2.30−0.86%−72.4%———$184.4M
ALXOALX Oncology Holdings$1.36+5.43%−34.9%———$188.1MCompare
WHWKWhitehawk Therapeutics$3.17+2.26%−23.6%———$180.7MCompare
AKBAAkebia Therapeutics$0.6947−4.28%−53.1%−21.4%−18.1%—$192.5MCompare
TRDAEntrada Therapeutics$5.06+7.20%−68.4%−53.9%−4762.0%—$197.0MCompare
ORMPOramed Pharmaceuticals$4.13+3.25%+5.4%——1.0$171.8MCompare
NAGENiagen Bioscience$2.52+6.78%−49.3%−4.3%3.2%12.5$199.4MCompare
PEPGPepGen$2.45−0.41%+32.8%———$169.7MCompare
SIONSionna Therapeutics$3.73+2.19%−91.4%———$168.6MCompare

News about BridgeBio Oncology Therapeutics

All news →

No recent articles focused on BridgeBio Oncology Therapeutics.

Quick answers

What does BridgeBio Oncology Therapeutics do?
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
What is BBOT's market cap?
$184.40M, based on the Nov 4 close of $2.30.
Does BridgeBio Oncology Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BBOT is sold short?
3.8M shares, 13.9% of float, as of Oct 15, 2026.
What sector is BBOT in?
Healthcare, in the Pharmaceuticals industry.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

HQ: South San Francisco, CA88 employeesListed Aug 12, 2025bridgebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology